Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer

  • Technology appraisal guidance
  • TA227
  • Published: 

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib: appeal

The Institute has received one appeal against the Final Appraisal Determination and Guidance on this technology. The Institute has arranged the hearing for the appeal received against the FAD for the above technology. The appeal panel will convene on Monday 16 May 2011 to hear oral representations from the appellants.

To register

The registration period for this appeal has now passed.

This page was last updated: 06 April 2011